We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo International Files BLA for Label Expansion of Xiaflex
Read MoreHide Full Article
Recently, Endo International plc ( announced that it has submitted a Biologics License Application (BLA) to the FDA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks. The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. The latest submission is based on positive results from two identical phase III RELEASE studies presented at the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC, and subsequently at the Aesthetic Meeting 2019 in New Orleans, LA. The studies showed that a greater percentage of the 843 women treated during the studies met the primary endpoint of response, with CCH versus placebo in both RELEASE-1 and RELEASE-2 studies.
Further, statistically significant improvements with the CCH versus placebo were observed for 8 of 8 (RELEASE-1) and 7 of 8 (RELEASE-2) secondary endpoints. All patient-centric endpoints displayed statistically significant improvement in the CCH group compared with the placebo group.
We note that CCH is currently marketed by the company under the brand name of Xiaflex for the treatment of Peyronie's disease (PD) and Dupuytren's contracture. The drug’s performance has been strong in the first half of 2019. The company is developing Xiaflex in partnership with BioSpecifics Technologies Corp. .
Shares of the company have plunged 52.3% year to date against the industry’s growth of 6.6%. However, the stock was up about 47% on Friday on the news of the finalization of a settlement agreement with two Ohio counties, County of Cuyahoga, and the County of Summit,in opioid-related litigation. Endo agreed to pay a total of $10 million to Cuyahoga and Summit counties. The company will also provide up to $1 million of its Vasostrict and Adrenalin products free of charge to these counties.
FibroGen’s loss per share estimates for 2019 narrowed from 87 cents to 37 cents, in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average being 346.59%.
VAXART’s loss per share estimates for the current year narrowed from $1.67 to $1.45, in the past 60 days. The company delivered a positive earnings surprise in one of the trailing four quarters, the average being 22%.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Endo International Files BLA for Label Expansion of Xiaflex
Recently, Endo International plc ( announced that it has submitted a Biologics License Application (BLA) to the FDA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks. The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. The latest submission is based on positive results from two identical phase III RELEASE studies presented at the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC, and subsequently at the Aesthetic Meeting 2019 in New Orleans, LA. The studies showed that a greater percentage of the 843 women treated during the studies met the primary endpoint of response, with CCH versus placebo in both RELEASE-1 and RELEASE-2 studies.
Further, statistically significant improvements with the CCH versus placebo were observed for 8 of 8 (RELEASE-1) and 7 of 8 (RELEASE-2) secondary endpoints. All patient-centric endpoints displayed statistically significant improvement in the CCH group compared with the placebo group.
We note that CCH is currently marketed by the company under the brand name of Xiaflex for the treatment of Peyronie's disease (PD) and Dupuytren's contracture. The drug’s performance has been strong in the first half of 2019. The company is developing Xiaflex in partnership with BioSpecifics Technologies Corp. .
Shares of the company have plunged 52.3% year to date against the industry’s growth of 6.6%. However, the stock was up about 47% on Friday on the news of the finalization of a settlement agreement with two Ohio counties, County of Cuyahoga, and the County of Summit,in opioid-related litigation. Endo agreed to pay a total of $10 million to Cuyahoga and Summit counties. The company will also provide up to $1 million of its Vasostrict and Adrenalin products free of charge to these counties.
Zacks Rank & Other Stocks to Consider
Endo currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are FibroGen Inc. (FGEN - Free Report) and VAXART INC. (VXRT - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
FibroGen’s loss per share estimates for 2019 narrowed from 87 cents to 37 cents, in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average being 346.59%.
VAXART’s loss per share estimates for the current year narrowed from $1.67 to $1.45, in the past 60 days. The company delivered a positive earnings surprise in one of the trailing four quarters, the average being 22%.
Endo International plc Price
Endo International plc price | Endo International plc Quote
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>